Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010


#30011

436pages

GlobalData

$ 5000

In Stock


GlobalData's pharmaceutical report, Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010 is an essential source of information and analysis on the global prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global prostate cancer therapeutics market. 

It analyses the treatment usage patterns in the global prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the global prostate cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized global prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
  • Analysis of the current and future market competition in the global Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the global prostate cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global prostate cancer therapeutics market till 2020.
  • Quantifying patient population in the global prostate cancer market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the global prostate cancer therapeutics market from 2001 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global prostate cancer therapeutics market landscape? Identify, understand and capitalize.
Table of content

1 Table of contents 3

1.1 List of Tables 8
1.2 List of Figures 12

2 Disease Overview 18
2.1 Overview 18
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 18
2.1.2 Jewett-Whitmore system 20
2.2 Epidemiology 20
2.3 Etiology 20
2.4 Symptoms 21
2.4.1 Localized or Locally Advanced Prostate Cancer 21
2.4.2 Metastatic Prostate Cancer 21
2.5 Diagnosis 21
2.5.1 Digital Rectal Examination 21
2.5.2 Prostate Specific Antigen Test 22
2.5.3 Transrectal Ultrasound 22
2.5.4 Prostate Biopsy 22
2.6 Pathology 23
2.6.1 Grading 23
2.7 Treatment 23
2.7.1 Watchful Waiting 23
2.7.2 Radiation therapy 24
2.7.3 Surgery 25
2.7.4 Hormone therapy 25
2.7.5 Chemotherapy Options 26
2.7.6 Other Treatments Being Studied 27
2.8 Treatment Guidelines 28

3 Market Characterization 29
3.1 Global 29
3.1.1 Market Size 29
3.1.2 Drivers & Barriers 40
3.1.3 Forecasts 42
3.1.4 Drug Sales 53
3.2 The US 58
3.2.1 Market Size 58
3.2.2 Drivers and Restraints 65
3.2.3 Forecasts 68
3.2.4 Drug Sales 75
3.2.5 Pricing & Reimbursements 78
3.3 The UK 79
3.3.1 Market Size 79
3.3.2 Drivers and Barriers 85
3.3.3 Impact on the Market 87
3.3.4 Forecasts 88
3.3.5 Drug Sales 94
3.3.6 Pricing and Reimbursements 97
3.4 Germany 99
3.4.1 Market Size 99
3.4.2 Drivers and Barriers 106
3.4.3 Impact on the Market 108
3.4.4 Forecasts 109
3.4.5 Drug Sales 116
3.4.6 Pricing & Reimbursements 120
3.5 France 121
3.5.1 Market Size 121
3.5.2 Drivers & Barriers 127
3.5.3 Impact on the Market 128
3.5.4 Forecasts 129
3.5.5 Drug Sales 136
3.5.6 Pricing & Reimbursements 139
3.6 Italy 140
3.6.1 Market Size 140
3.6.2 Drivers & Barriers 146
3.6.3 Impact on the Market 148
3.6.4 Forecasts 149
3.6.5 Drug Sales 155
3.6.6 Pricing and Reimbursements 159
3.7 Spain 160
3.7.1 Market Size 160
3.7.2 Drivers and Barriers 166
3.7.3 Impact on the Market 167
3.7.4 Forecasts 168
3.7.5 Drug Sales 175
3.7.6 Pricing and Reimbursements 179
3.8 Japan 180
3.8.1 Market Size 180
3.8.2 Drivers and Barriers 185
3.8.3 Impact on the Market 186
3.8.4 Forecasts 187
3.8.5 Future Impact 192
3.8.6 Drug Sales 193
3.8.7 Pricing & Reimbursements 196
3.9 Brazil 197
3.9.1 Market Size 197
3.9.2 Drivers and Restraints 202
3.9.3 Impact on the Market 203
3.9.4 Forecasts 204
3.9.5 Future Impact 209
3.10 Russia 210
3.10.1 Market Size 210
3.10.2 Drivers and Restraints 215
3.10.3 Impact on the Market 216
3.10.4 Forecasts 217
3.10.5 Future Impact 222
3.11 India 223
3.11.1 Market Size (2001-2009) 223
3.11.2 Drivers and Restraints 228
3.11.3 Impact on the Market 229
3.11.4 Forecasts (2010-2020) 230
3.11.5 Future Impact 235
3.12 China 236
3.12.1 Market Size (2001-2009) 236
3.12.2 Drivers and Restraints 241
3.12.3 Impact on the Market 242
3.12.4 Forecasts (2010-2020) 243
3.12.5 Future Impact 248
3.13 Key Takeaway 248

4 Competitor Assessment 249
4.1 Strategic Competitor Assessment 249
4.1.1 Overview 249
4.1.2 Benchmarking 249
4.1.3 Current Competitor Assessment 253
4.2 Launch Analysis and Sales Forecasts 255
4.3 Product Profiles 256
4.3.1 Taxotere (docetaxel) 257
4.3.2 Casodex (Bicalutamide) 261
4.3.3 Zoladex (Goserelin) 266
4.3.4 Provenge (sipuleucel-T) 267
4.3.5 Jevtana (cabazitaxel) 270
4.3.6 Eligard (leuprolide acetate) 272
4.3.7 Lupron (Leuprolide acetate) 276
4.3.8 Prostap (leuprolide acetate) 279
4.3.9 Firmagon (degarelix) 281
4.3.10 Vantas (Histrelin) 283
4.3.11 Novantrone (Mitoxantrone hydrochloride) 285
4.3.12 Emcyt (estramustine) 287
4.3.13 Trelstar (triptorelin) 289
4.3.14 Eulexin 290
4.3.15 Delestrogen 292
4.3.16 Gynodiol 293
4.3.17 Estrace tablet 293
4.3.18 Tace 294
4.3.19 Nilandrone 295
4.3.20 Premarin 296
4.3.21 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 297
5 Pipeline Assessment 298
5.1 Overview 298
5.2 Pipeline Analysis by Phase of Development 299
5.3 Pipeline by Mechanism of Action 300
5.4 Strategic Pipeline Assessment 301
5.4.1 Technology Trends Analytical Framework 301
5.5 Trends in Prostate Cancer Pipeline 302
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 302
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 302
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 302
5.6 Partners in Research and Development 303
5.6.1 Licensing Agreements by Phase of Development 303
5.6.2 Licensing Agreements by Geography 306
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 306
5.7 Most Promising Drugs Profiles 308
5.7.1 Aflibercept (VEGF Trap) 309
5.7.2 Ipilimumab 311
5.7.3 Abiraterone Acetate (CB7630) 314
5.7.4 Zibotentan (ZD4054) 317
5.7.5 Sprycel (dasatinib) 319
5.7.6 MDV3100 321
5.8 Prostate Cancer Pipeline Pre-clinical Phase 324
5.9 Prostate Cancer Pipeline Phase I 326
5.10 Prostate Cancer Pipeline Phase II 329
5.11 Prostate Cancer Pipeline Phase III 338
5.12 Key Takeaway 340

6 Unmet Need and Target Product Profile 341
6.1 Unmet Need 343
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 343
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 344
6.2 Opportunity for Target Product 345
6.3 Target Product Profile 347
6.3.1 Ideal Characteristics 347
6.3.2 Target Product Description 348
6.4 Key Takeaway 348

7 Strategic Assessment 349
7.1 Key Events Impacting the Future Market 349
7.2 Market Impact Analysis 350
7.3 Future Market Scenario 350
7.4 Company Analysis 352
7.4.1 Market Leadership 352
7.4.2 Future Players in the Market 352
7.5 Key Takeaway 353

8 Company Profiles 354
8.1 Sanofi-aventis 354
8.1.1 Business Description 354
8.1.2 Financial Overview 356
8.1.3 SWOT Analysis 356
8.1.4 Oncology Focus 361
8.2 Pfizer Inc. 362
8.2.1 Business Description 362
8.2.2 Financial Overview 363
8.2.3 SWOT Analysis 363
8.2.4 Oncology Focus 369
8.3 AstraZeneca 371
8.3.1 Business Description 371
8.3.2 Financial Overview 372
8.3.3 SWOT Analysis 373
8.3.4 Oncology Focus 376
8.4 Bristol-Myers Squibb 379
8.4.1 Business Description 379
8.4.2 Financial Overview 380
8.4.3 SWOT Analysis 380
8.4.4 Oncology Focus 386
8.5 Medivation 387
8.5.1 Business Description 387
8.5.2 SWOT Analysis 388
8.5.3 Oncology Focus 391
8.6 Takeda Pharmaceuticals 392
8.6.1 Business Description 392
8.6.2 SWOT Analysis 392
8.7 Dendreon Corporation 394
8.7.1 Business Description 394
8.7.2 SWOT Analysis 394
8.8 Johnson and Johnson 398
8.8.1 Business Description 398
8.8.2 SWOT Analysis 399
8.8.3 Oncology Focus 405
8.9 Auron Healthcare GmbH 406
8.9.1 Business Description 406
8.10 Oncogenex Pharmaceuticals, Inc. 406
8.10.1 Business Description 406
8.11 Agennix AG 406
8.11.1 Business Description 406
8.12 GTx, Inc. 407
8.12.1 Business Description 407
8.13 GlaxoSmithKline plc. 407
8.13.1 Business Description 407
8.13.2 Financial Overview 408
8.13.3 SWOT Analysis 408
8.13.4 Oncology Focus 414

9 M&A Analysis 416
9.1 Key Highlights 416
9.2 Key Deals Analysis 417
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 417
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 417
9.2.3 Tolmar Holding Acquires QLT USA from QLT 418
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 418
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 418
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 418
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 418
9.2.8 GPC Biotech Merges with Agennix 418
9.2.9 Eli Lilly Acquires ImClone 419
9.2.10 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 419
9.3 M&A Deals by Geography 420
9.4 M&A Deals by Deal Size 420

10 Expert Opinion 421
10.1 US 421
10.2 UK 422
10.3 Germany 423
10.4 France 424
10.5 Italy 425
10.6 Spain 426
10.7 Japan 427

11 Appendix 428
11.1 Market Definitions 428
11.2 Abbreviations 428
11.3 Research Methodology 430
11.3.1 Coverage 430
11.3.2 Secondary Research 431
11.3.3 Forecasting 431
11.3.4 Primary Research 434
11.3.5 Expert Panel validation 434
11.3.6 Contact Us 434
11.3.7 Disclaimer 434

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 19
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 22
Table 3: Prostate Cancer, Global, Sales Value ($m), 2001-2009 29
Table 4: Prostate Cancer, Top Seven Countries, Sales Value ($m), 2001-2009 30
Table 5: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2001-2009 32
Table 6: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 33
Table 7: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2001-2009 34
Table 8: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2001-2009 35
Table 9: Prostate Cancer, Top Seven Countries, Patient Volume, 2001-2009 36
Table 10: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2001-2009 37
Table 11: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2001-2009 38
Table 12: Prostate Cancer Therapeutics Market, Global, Sales Value ($m), 2009-2020 42
Table 13: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m), 2009-2020 43
Table 14: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2009-2020 44
Table 15: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2020 45
Table 16: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2009-2020 46
Table 17: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2009-2020 47
Table 18: Prostate Cancer Therapeutics Market, Top Seven Countries, Patient Volume (000s), 2009-2020 48
Table 19: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2009-2020 49
Table 20: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2009-2020 50
Table 21: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 54
Table 22: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 54
Table 23: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 56
Table 24: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 56
Table 25: Prostate Cancer Therapeutics Market, US, Sales Value ($bn), 2001-2009 58
Table 26: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 60
Table 27: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2001-2009 61
Table 28: Prostate Cancer Therapeutics Market, The US, Treatment Usage Patterns (000s), 2001-2009 63
Table 29: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 68
Table 30: Prostate Cancer, US, Annual Cost of Therapy ($), 2009-2020 69
Table 31: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2009-2020 70
Table 32: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2009-2020 72
Table 33: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 76
Table 34: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 76
Table 35: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2001-2009 79
Table 36: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2001-2009 80
Table 37: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2001-2009 81
Table 38: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2001-2009 83
Table 39: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2009-2020 88
Table 40: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2009-2020 89
Table 41: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2009-2020 90
Table 42: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2009-2020 92
Table 43: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 95
Table 44: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 95
Table 45: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 97
Table 46: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 97
Table 47: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 99
Table 48: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 101
Table 49: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2001-2009 102
Table 50: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2001-2009 103
Table 51: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 109
Table 52: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 110
Table 53: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2009-2020 111
Table 54: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2009-2020 113
Table 55: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 117
Table 56: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 117
Table 57: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 119
Table 58: Prostate Cancer, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 119
Table 59: Prostate Cancer, France, Sales Value ($m), 2001-2009 121
Table 60: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009 123
Table 61: Prostate Cancer Therapeutics Market, France, Patient Volume (000s), 2001-2009 124
Table 62: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (000s), 2001-2009 125
Table 63: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020 129
Table 64: Prostate Cancer, France, Annual Cost of Therapy ($), 2009-2020 130
Table 65: Prostate Cancer Therapeutics Market, France, Patient Volume (000s), 2009-2020 132
Table 66: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (000s), 2009-2020 133
Table 67: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 137
Table 68: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2009-2020 137
Table 69: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 139
Table 70: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2009-2020 139
Table 71: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 140
Table 72: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 141
Table 73: Prostate Cancer Therapeutics Market, Italy, Patient Volume (000s), 2001-2009 143
Table 74: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (000s), 2001-2009 144
Table 75: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 149
Table 76: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 150
Table 77: Prostate Cancer Therapeutics Market, Italy, Patient Volume (000s), 2009-2020 151
Table 78: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (000s), 2009-2020 152
Table 79: Prostate Cancer Therapeutics Market, France, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 156
Table 80: Prostate Cancer Therapeutics Market, France, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 156
Table 81: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 158
Table 82: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 158
Table 83: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 160
Table 84: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 161
Table 85: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2001-2009 162
Table 86: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2001-2009 164
Table 87: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 168
Table 88: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 169
Table 89: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2009-2020 170
Table 90: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2009-2020 172
Table 91: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 176
Table 92: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 176
Table 93: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 178
Table 94: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 178
Table 95: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009 180
Table 96: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 181
Table 97: Prostate Cancer Therapeutics Market, Japan, Patient Volume (000s), 2001-2009 182
Table 98: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (000s), 2001-2009 183
Table 99: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020 187
Table 100: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020 188
Table 101: Prostate Cancer Therapeutics Market, Japan, Patient Volume (000s), 2009-2020 189
Table 102: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (000s), 2009-2020 190
Table 103: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 194
Table 104: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 194
Table 105: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 194
Table 106: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 196
Table 107: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 196
Table 108: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 197
Table 109:Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 198
Table 110: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (000s), 2001-2009 199
Table 111:Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (000s), 2001-2009 200
Table 112:Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 204
Table 113:Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 205
Table 114: Prostate Cancer, Brazil, Patient Volume (000s), 2009-2020 206
Table 115: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (000s), 2009-2020 207
Table 116: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 210
Table 117: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 211
Table 118: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 212
Table 119: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 213
Table 120: Prostate Cancer, Russia, Sales Value ($m), 2009-2020 217
Table 121: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2009-2020 218
Table 122: Prostate Cancer, Russia, Patient Volume (Thousands), 2009-2020 219
Table 123: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 220
Table 124: Prostate Cancer, India, Sales Value ($m), 2001-2009 223
Table 125: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 224
Table 126: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 225
Table 127: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 226
Table 128: Prostate Cancer, India, Sales Value ($m), 2009-2020 230
Table 129: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 231
Table 130: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 232
Table 131: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 233
Table 132: Prostate Cancer, China, Sales Value ($m), 2001-2009 236
Table 133: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 237
Table 134: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 238
Table 135: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 239
Table 136: Prostate Cancer, China, Sales Value ($m), 2009-2020 243
Table 137: Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 244
Table 138: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 245
Table 139: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 246
Table 140: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 250
Table 141: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 251
Table 142:Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 252
Table 143: Prostate Cancer, Global, Benchmarking Major Marketed Products, 2010 256
Table 144: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 262
Table 145: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 272
Table 146: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 273
Table 147: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 274
Table 148: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 276
Table 149: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 277
Table 150: Prostate Cancer, Global, Licensing Agreements, 2009-2010 305
Table 151: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 307
Table 152: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 308
Table 153: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 324
Table 154: Prostate Cancer, Global, Phase I Pipeline, August 2010 326
Table 155: Prostate Cancer, Global, Phase II Pipeline, August 2010 329
Table 156: Prostate Cancer, Global, Phase III Pipeline, August 2010 338
Table 157:Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 347
Table 158:Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 348
Table 159:Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 405
Table 160: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 406
Table 161: Prostate Cancer, Global, M&A Deals by Geography, 2010 416
Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 28
Figure 2: Prostate Cancer, Global, Sales Value ($m), 2001-2009 29
Figure 3: Prostate Cancer, Top Seven Countries, Sales Value ($m), 2001-2009 30
Figure 4: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2001-2009 31
Figure 5: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 33
Figure 6: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2001-2009 34
Figure 7: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2001-2009 35
Figure 8: Prostate Cancer Therapeutics Market, Top Seven Countries , Patient Volume (000s), 2001-2009 36
Figure 9: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2001-2009 37
Figure 10: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2001-2009 38
Figure 11: Prostate Cancer, Global, Market Drivers and Restraints, 2009 40
Figure 12: Prostate Cancer Therapeutics Market, Global, Historical Events Impact on the Market, 2010 41
Figure 13: Prostate Cancer Therapeutics Market, Global, Sales Value ($m), 2009-2020 42
Figure 14: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m), 2009-2020 43
Figure 15: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2009-2020 44
Figure 16: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2020 45
Figure 17: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2009-2020 46
Figure 18: Prostate Cancer Therapeutics Market, Global, Patient Volume (000s), 2009-2020 47
Figure 19: Prostate Cancer Therapeutics Market, Top Seven Countries, Patient Volume (000s), 2009-2020 48
Figure 20: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (000s), 2009-2020 49
Figure 21: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (000s), 2009-2020 50
Figure 22: Prostate Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2009-2020 52
Figure 23: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 53
Figure 24: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 55
Figure 25: Prostate Cancer Therapeutics Market, Global, Breakdown of Drug Sales (%), 2009 57
Figure 26: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2001-2009 58
Figure 27: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 60
Figure 28: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2001-2009 61
Figure 29: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2001-2009 63
Figure 30: Prostate Cancer Therapeutics Market, US, Market Drivers and Restraints, 2009 65
Figure 31: Prostate Cancer Therapeutics Market, The US, Historical Events Impact on the Market, 2010 67
Figure 32: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 68
Figure 33: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2009-2020 69
Figure 34: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2009-2020 70
Figure 35: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2009-2020 71
Figure 36: Prostate Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2010-2020 74
Figure 37: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 75
Figure 38: Prostate Cancer Therapeutics Market, US, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 77
Figure 39: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2001-2009 79
Figure 40: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2001-2009 80
Figure 41: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2001-2009 81
Figure 42: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2001-2009 83
Figure 43: Prostate Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2009 85
Figure 44: Prostate Cancer Therapeutics Market, The UK, Historical Events Impact on the Market, 2010 87
Figure 45: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2009-2020 88
Figure 46: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2009-2020 89
Figure 47: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2009-2020 90
Figure 48: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2009-2020 91
Figure 49: Prostate Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2009-2020 93
Figure 50: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 94
Figure 51: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 96
Figure 52: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 99
Figure 53: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 101
Figure 54: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2001-2009 102
Figure 55: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2001-2009 103
Figure 56: Prostate Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 106
Figure 57: Prostate Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010 108
Figure 58: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 109
Figure 59: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 110
Figure 60: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2009-2020 111
Figure 61: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2009-2020 112
Figure 62: Prostate Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2009-2020 115
Figure 63: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 116
Figure 64: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 118
Figure 65: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2001-2009 121
Figure 66: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009 123
Figure 67: Prostate Cancer Therapeutics Market, France, Patient Volume (000s), 2001-2009 124
Figure 68: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (000s), 2001-2009 125
Figure 69: Prostate Cancer, France, Market Drivers and Restraints, 2009 127
Figure 70: Prostate Cancer, France, Historical Events Impact on the Market, 2010 128
Figure 71: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020 129
Figure 72: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009-2020 130
Figure 73: Prostate Cancer Therapeutics Market, France, Patient Volume (000s), 2009-2020 131
Figure 74: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (000s), 2009-2020 133
Figure 75: Prostate Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009-2020 135
Figure 76: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 136
Figure 77: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 138
Figure 78: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 140
Figure 79: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 141
Figure 80: Prostate Cancer Therapeutics Market, Italy, Patient Volume (000s), 2001-2009 143
Figure 81: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (000s), 2001-2009 144
Figure 82: Prostate Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 146
Figure 83: Prostate Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010 148
Figure 84: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 149
Figure 85: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 150
Figure 86: Prostate Cancer Therapeutics Market, Italy, Patient Volume (000s), 2009-2020 151
Figure 87: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (000s), 2009-2020 152
Figure 88: Prostate Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2009-2020 154
Figure 89: Prostate Cancer Therapeutics Market, Italy, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 155
Figure 90: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 157
Figure 91: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 160
Figure 92: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 161
Figure 93: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2001-2009 162
Figure 94: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2001-2009 164
Figure 95: Prostate Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 166
Figure 96: Prostate Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010 167
Figure 97: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 168
Figure 98: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 169
Figure 99: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2009-2020 170
Figure 100: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2009-2020 172
Figure 101: Prostate Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2009-2020 174
Figure 102: Prostate Cancer Therapeutics Market, Spain, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 175
Figure 103: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 177
Figure 104: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009 180
Figure 105: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 181
Figure 106: Prostate Cancer Therapeutics Market, Japan, Patient Volume (000s), 2001-2009 182
Figure 107: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (000s), 2001-2009 183
Figure 108: Prostate Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009 185
Figure 109: Prostate Cancer Therapeutics Market, Japan, Historical Events Impact on the Market, 2010 186
Figure 110: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020 187
Figure 111: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020 188
Figure 112: Prostate Cancer Therapeutics Market, Japan, Patient Volume (000s), 2009-2020 189
Figure 113: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (000s), 2009-2020 190
Figure 114: Prostate Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010 192
Figure 115: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2020 193
Figure 116: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 195
Figure 117: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009 197
Figure 118: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009 198
Figure 119: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (000s), 2001-2009 199
Figure 120: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (000s), 2001-2009 200
Figure 121: Prostate Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 202
Figure 122: Prostate Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010 203
Figure 123: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020 204
Figure 124: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020 205
Figure 125: Prostate Cancer Therapeutics Market, Brazil, Patient Volume (000s), 2009-2020 206
Figure 126: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns (000s), 2009-2020 207
Figure 127: Prostate Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010 209
Figure 128: Prostate Cancer, Russia, Sales Value ($m), 2001-2009 210
Figure 129: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009 211
Figure 130: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009 212
Figure 131: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009 213
Figure 132: Prostate Cancer, Russia, Market Drivers and Restraints, 2009 215
Figure 133: Prostate Cancer, Russia, Historical Events Impact on the Market, 2010 216
Figure 134: Prostate Cancer, Russia , Sales Value ($m), 2009-2020 217
Figure 135: Prostate Cancer, Russia , Annual Cost of Therapy ($), 2009-2020 218
Figure 136: Prostate Cancer, Russia , Patient Volume (Thousands), 2009-2020 219
Figure 137: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020 220
Figure 138: Prostate Cancer, Russia, Future Events Expected to Impact the Market, 2010 222
Figure 139: Prostate Cancer, India, Sales Value ($m), 2001-2009 223
Figure 140: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009 224
Figure 141: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009 225
Figure 142: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009 226
Figure 143: Prostate Cancer, India, Market Drivers and Restraints, 2009 228
Figure 144: Prostate Cancer, India, Historical Events and Their Impact on the Market, 2010 229
Figure 145: Prostate Cancer, India, Sales Value ($m), 2009-2020 230
Figure 146: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020 231
Figure 147: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020 232
Figure 148: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020 233
Figure 149: Prostate Cancer, India, Future Events Expected to Affect the Market, 2010 235
Figure 150: Prostate Cancer, China, Sales Value ($m), 2001-2009 236
Figure 151: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009 237
Figure 152: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009 238
Figure 153: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009 239
Figure 154: Prostate Cancer, China, Market Drivers and Restraints, 2009 241
Figure 155: Prostate Cancer, China, Historical Events and Their Impact on the Market, 2010 242
Figure 156: Prostate Cancer, China, Sales Value ($m), 2009-2020 243
Figure 157 Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020 244
Figure 158: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020 245
Figure 159: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020 246
Figure 160: Prostate Cancer, China, Future Events Expected to Impact the Market, 2010 248
Figure 161: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 253
Figure 162: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 254
Figure 163: Prostate Cancer Therapeutics Market, Global, Sales Forecast by Therapies, 2001-2020 255
Figure 164: Prostate Cancer, Global, Taxotere, Chemical Structure 257
Figure 165: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 259
Figure 166: Prostate Cancer, Global, Taxotere, Sales ($m), 2004-2020 260
Figure 167: Prostate Cancer, Global, Casodex, Chemical Structure 261
Figure 168: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010 264
Figure 169: Prostate Cancer, Global, Casodex, Sales ($m), 2001-2020 265
Figure 170: Prostate Cancer, Global, Zoladex, Chemical Structure 266
Figure 171: Prostate Cancer, Global, Zoladex, Sales Forecast ($m), 2001-2020 267
Figure 172: Prostate Cancer, Global, Provenge, Sales Forecast ($m), 2009-2020 269
Figure 173: Prostate Cancer, Global, Jevtana, Sales Forecast ($m), 2001-2020 271
Figure 174: Prostate Cancer, Global, Eligard , Chemical Structure 272
Figure 175: Prostate Cancer, Global, Leuprolide (Eligard, Lupron, Prostap), Sales Forecast ($m), 2001-2020 275
Figure 176: Prostate Cancer, Global, Lupron, Chemical Structure 276
Figure 177: Prostate Cancer, Global, Leuprolide (Eligard, Lupron, Prostap), Sales Forecast ($m), 2001-2020 279
Figure 178: Prostate Cancer, Global, Leuprolide (Eligard, Lupron, Prostap), Sales Forecast ($m), 2001-2020 280
Figure 179: Prostate Cancer, Global, Firmagon, Chemical Structure 281
Figure 180: Prostate Cancer, Global, Firmagon, Sales Forecast ($m), 2008-2020 282
Figure 181: Prostate Cancer, Global, Vantas, Chemical Structure 283
Figure 182: Prostate Cancer, Global, Vantas, Sales Forecast ($m), 2004-2020 285
Figure 183: Prostate Cancer, Global, Novatrone, Chemical Structure 286
Figure 184: Prostate Cancer, Global, Mitoxantrone, Sales Forecast ($m), 2001-2020 287
Figure 185: Prostate Cancer, Global, Emcyt, Chemical Structure 288
Figure 186: Prostate Cancer, Global, Estramustine, Sales Forecast ($m), 2001-2020 288
Figure 187: Prostate Cancer, Global, Trelstar, Chemical Structure 289
Figure 188: Prostate Cancer, Global, Eulexin, Chemical Structure 290
Figure 189: Prostate Cancer, Global, Delestrogen, Chemical Structure 292
Figure 190: Prostate Cancer, Global, Gynodiol, Chemical Structure 293
Figure 191: Prostate Cancer, Global, Estrace, Chemical Structure 294
Figure 192: Prostate Cancer, Global, Tace, Chemical Structure 295
Figure 193: Prostate Cancer, Global, Nilandrone, Chemical Structure 295
Figure 194: Prostate Cancer, Global, Premarin, Chemical Structure 296
Figure 195: Prostate Cancer, Global, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 297
Figure 196: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 298
Figure 197: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 299
Figure 198: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 300
Figure 199: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 301
Figure 200: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 302
Figure 201: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 303
Figure 202: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 306
Figure 203: Prostate Cancer, Global, Aflibercept, Chemical Structure 309
Figure 204: Prostate Cancer, Global, Aflibercept, Sales Forecast ($m), 2009-2020 311
Figure 205: Prostate Cancer, Global, Ipilimumab , Sales Forecast ($m), 2009-2020 313
Figure 206: Prostate Cancer, Global, Abiraterone, Chemical Structure 314
Figure 207: Prostate Cancer, Global, Abiraterone, Sales Forecast ($m), 2009-2020 316
Figure 208: Prostate Cancer, Global, Zibotentan, Chemical Structure 317
Figure 209: Prostate Cancer, Global, Zibotentan , Sales Forecast ($m), 2009-2020 319
Figure 210: Prostate Cancer, Global, Sprycel , Sales Forecast ($m), 2009-2020 320
Figure 211: Prostate Cancer, Global, MDV3100, Chemical Structure 321
Figure 212: Prostate Cancer, Global, MDV3100 , Sales Forecast ($m), 2009-2020 323
Figure 213: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 341
Figure 214: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 342
Figure 215: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 342
Figure 216: Prostate Cancer, Global, Prostate Cancer, Opportunity and Unmet Need, 2010 343
Figure 217: Prostate Cancer, Global, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 346
Figure 218: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 346
Figure 219: Prostate Cancer, Global, Key Events Impacting the Future Market 349
Figure 220: Prostate Cancer, Global, Implications for Future Market Competition, 2010 350
Figure 221: Prostate Cancer, Global, Future Players in the Market, 2010 352
Figure 222:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 354
Figure 223: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 355
Figure 224: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 356
Figure 225: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 361
Figure 226: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 363
Figure 227: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 369
Figure 228: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 370
Figure 229: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 372
Figure 230: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 373
Figure 231: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 377
Figure 232: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 377
Figure 233: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 378
Figure 234: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 379
Figure 235: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 380
Figure 236: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 386
Figure 237: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 387
Figure 238: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 388
Figure 239: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 392
Figure 240: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 394
Figure 241: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 399
Figure 242: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 405
Figure 243: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 408
Figure 244: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 414
Figure 245: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 415
Figure 246: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 420
Figure 247: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 420
Figure 248: Prostate Cancer, US, Key Data Inputs from KOL Interviews, July 2010 421
Figure 249: Prostate Cancer, UK, Key Data Inputs from KOL Interviews, July 2010 422
Figure 250: Prostate Cancer, Germany, Key Data Inputs from KOL Interviews, July 2010 423
Figure 251: Prostate Cancer, France, Key Data Inputs from KOL Interviews, July 2010 424
Figure 252: Prostate Cancer, Italy, Key Data Inputs from KOL Interviews, July 2010 425
Figure 253: Prostate Cancer, Spain, Key Data Inputs from KOL Interviews, July 2010 426